TSHR; NMUR2; | |
ADRA2C; ADRA2A; | |
GAA; MGAM; ACHE; | |
TDP1; BLM; PKM; HSD17B1; NOX4; ALOX15; USP2; TNKS; TNKS2; AOX1; POLB; | |
CFTR; | |
GSK3B; SYK; FLT3; ABL1; MAPK1; EGFR; CDK6; CSNK2A1; | |
CA12; CA7; CA4; | |
AR; | |
ESR2; ESR1; | |
ESRRB; ESRRA; | |
MAOA; PTGS2; ALDH2; XDH; | |
HIF1A; TP53; NFKB1; | |
ABCG2; ABCC1; | |
SLCO1B3; SLCO1B1; | |
LMNA; RAB9A; NPC1; MAPT; THPO; TTR; | |
L3MBTL1; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Hydrolase | MGAM | Maltase-glucoamylase | O43451 | CHEMBL2074 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Oxidoreductase | ALDH2 | Aldehyde dehydrogenase | P05091 | CHEMBL1935 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | ABL1 | Tyrosine-protein kinase ABL | P00519 | CHEMBL1862 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.208E-12 | 4.385E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.606E-12 | 8.105E-09 | ALOX15, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, TBXAS1, XDH |
MF | GO:0005488; binding | GO:0020037; heme binding | 7.745E-12 | 1.205E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, NOX4, PTGS2, TBXAS1 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 6.613E-11 | 6.261E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.103E-10 | 1.001E-07 | ABL1, CA7, CFTR, EGFR, HIF1A, MAPK1, NPC1, PTGS2, SYK, TNKS, TNKS2 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 2.691E-10 | 2.092E-07 | AR, CYP3A4, ESR1, ESR2, ESRRA, ESRRB, HSD17B1, NPC1 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.344E-09 | 7.136E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 2.288E-09 | 1.132E-06 | ABL1, ADRA2A, CA7, CDK6, CFTR, EGFR, HIF1A, MAPK1, NPC1, PTGS2, SYK, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.200E-09 | 2.097E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 8.557E-09 | 3.106E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.371E-08 | 1.286E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.196E-07 | 2.913E-05 | CYP1A2, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 2.513E-07 | 5.700E-05 | AR, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.149E-06 | 1.962E-04 | ALDH2, AOX1, CYP19A1, CYP1A2, NOX4, XDH |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.929E-06 | 3.043E-04 | ABCC1, ADRA2A, CA4, EGFR, SLCO1B1, SLCO1B3, TSHR |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 4.723E-06 | 6.635E-04 | CFTR, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, EGFR, NOX4, PTGS2, RAB9A, TBXAS1 |
BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 4.856E-06 | 6.779E-04 | AR, CYP19A1, ESR1 |
BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 5.207E-06 | 7.131E-04 | ABL1, CDK6, EGFR, GSK3B, HIF1A, MAPK1, MAPT, PTGS2, SYK, TP53, XDH |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 6.460E-06 | 8.684E-04 | CYP1A2, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 7.419E-06 | 9.674E-04 | AR, BLM, CA12, CA4, CA7, ESR1, ESR2, ESRRA, ESRRB, L3MBTL1, TNKS, TP53 |
BP | GO:0008152; metabolic process | GO:0009115; xanthine catabolic process | 9.810E-06 | 1.187E-03 | AOX1, XDH |
BP | GO:0065007; biological regulation | GO:0043006; activation of phospholipase A2 activity by calcium-mediated signaling | 9.810E-06 | 1.187E-03 | EGFR, NMUR2 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 9.810E-06 | 1.187E-03 | ESR1, ESR2 |
BP | GO:0032502; developmental process | GO:0048732; gland development | 1.090E-05 | 1.304E-03 | ABL1, AR, CSNK2A1, CYP19A1, EGFR, MAPK1, PKM |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.112E-05 | 1.323E-03 | CA12, CA4, CA7, CFTR |
BP | GO:0008152; metabolic process | GO:0022900; electron transport chain | 1.203E-05 | 1.424E-03 | ALDH2, AOX1, CYP19A1, CYP1A2, NOX4, XDH |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.327E-05 | 1.545E-03 | CA12, CA4, CA7 |
BP | GO:0002376; immune system process | GO:0048534; hematopoietic or lymphoid organ development | 1.430E-05 | 1.605E-03 | ABL1, FLT3, HIF1A, L3MBTL1, MAPK1, POLB |
BP | GO:0008152; metabolic process | GO:0050731; positive regulation of peptidyl-tyrosine phosphorylation | 1.747E-05 | 1.915E-03 | ABL1, ADRA2A, ADRA2C, FLT3, SYK, TP53 |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 1.975E-05 | 2.097E-03 | MAPK1, TNKS, TNKS2 |
BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 2.104E-05 | 2.193E-03 | ABL1, ALOX15, GSK3B, HIF1A, MAPK1, MAPT, NOX4, TNKS, TNKS2, TP53 |
BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 2.309E-05 | 2.394E-03 | ABL1, CYP1B1, EGFR, MAPK1, TP53 |
BP | GO:0008152; metabolic process | GO:0000023; maltose metabolic process | 2.937E-05 | 2.855E-03 | GAA, MGAM |
BP | GO:0002376; immune system process | GO:0001922; B-1 B cell homeostasis | 2.937E-05 | 2.855E-03 | ABL1, HIF1A |
MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 2.937E-05 | 2.855E-03 | ALOX15, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 2.937E-05 | 2.855E-03 | CYP1A1, CYP3A4 |
MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 2.937E-05 | 2.855E-03 | ADRA2A, ADRA2C |
MF | GO:0003824; catalytic activity | GO:0032450; maltose alpha-glucosidase activity | 2.937E-05 | 2.855E-03 | GAA, MGAM |
BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 3.288E-05 | 3.154E-03 | EGFR, ESRRB, HIF1A |
MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 3.408E-05 | 3.241E-03 | ABCG2, ACHE, ADRA2A, ADRA2C, AOX1, BLM, FLT3, MAPT, NFKB1, PTGS2, XDH |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 3.827E-05 | 3.561E-03 | CYP1A1, POLB, TP53 |
BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 4.486E-05 | 4.088E-03 | CYP1A2, EGFR, ESR1, ESRRA, PTGS2 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 5.073E-05 | 4.491E-03 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 5.221E-05 | 4.561E-03 | ABL1, ACHE, ADRA2A, CSNK2A1, EGFR, ESRRB, FLT3, L3MBTL1, MAPT, PKM, SYK, TSHR |
BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 5.622E-05 | 4.799E-03 | AR, ESR1, ESR2, ESRRA, ESRRB |
BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 5.862E-05 | 4.799E-03 | ADRA2A, ADRA2C |
BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 5.862E-05 | 4.799E-03 | ADRA2A, ADRA2C |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 5.862E-05 | 4.799E-03 | TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 5.862E-05 | 4.799E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 5.862E-05 | 4.799E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0004558; alpha-1,4-glucosidase activity | 5.862E-05 | 4.799E-03 | GAA, MGAM |
BP | GO:0008152; metabolic process | GO:0044283; small molecule biosynthetic process | 6.848E-05 | 5.544E-03 | ALOX15, CFTR, CYP19A1, CYP1A1, CYP3A4, PKM, PTGS2, SYK |
MF | GO:0005488; binding | GO:0002039; p53 binding | 7.062E-05 | 5.695E-03 | BLM, GSK3B, HIF1A, TP53 |
BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 7.182E-05 | 5.771E-03 | ABL1, ADRA2A, EGFR, HIF1A, MAPK1, NOX4, PTGS2, TP53 |
BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 7.398E-05 | 5.879E-03 | CYP19A1, CYP1A2, CYP3A4 |
MF | GO:0005488; binding | GO:0019901; protein kinase binding | 7.828E-05 | 6.198E-03 | ABL1, ADRA2A, EGFR, ESR1, GSK3B, HIF1A, MAPK1, SYK, TP53 |
BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 8.304E-05 | 6.505E-03 | CYP1B1, HIF1A, PTGS2 |
BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 9.280E-05 | 7.041E-03 | CYP19A1, CYP3A4, ESR1 |
MF | GO:0005215; transporter activity | GO:0005319; lipid transporter activity | 9.134E-05 | 7.041E-03 | ABCC1, ABCG2, NPC1, SLCO1B1, SLCO1B3 |
BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 9.659E-05 | 7.149E-03 | ABL1, ACHE, CFTR, EGFR, HIF1A, SYK |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 9.743E-05 | 7.149E-03 | CSNK2A1, EGFR, FLT3, PKM |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 9.750E-05 | 7.149E-03 | CYP1A1, CYP3A4 |
BP | GO:0009987; cellular process | GO:1901216; positive regulation of neuron death | 1.025E-04 | 7.466E-03 | ABL1, GSK3B, MAPT, TP53 |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 1.078E-04 | 7.799E-03 | CSNK2A1, GSK3B, MAPK1, TNKS |
BP | GO:0008152; metabolic process | GO:0031324; negative regulation of cellular metabolic process | 1.191E-04 | 8.422E-03 | ABL1, ADRA2A, AR, BLM, CSNK2A1, ESR1, ESR2, ESRRA, GSK3B, HIF1A, L3MBTL1, MAPT, NFKB1, NPC1, PTGS2, TNKS, TNKS2, TP53, USP2, XDH |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.265E-04 | 8.827E-03 | CYP1A2, EGFR, MAPK1 |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 1.265E-04 | 8.827E-03 | ABCC1, ALOX15, SYK |
BP | GO:0050896; response to stimulus | GO:0033273; response to vitamin | 1.310E-04 | 9.053E-03 | CYP1A1, EGFR, PTGS2, TP53 |
MF | GO:0005488; binding | GO:0008013; beta-catenin binding | 1.310E-04 | 9.053E-03 | AR, CSNK2A1, ESR1, GSK3B |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 1.392E-04 | 9.565E-03 | CSNK2A1, HIF1A, MAPT |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.460E-04 | 9.779E-03 | CYP1A1, CYP3A4 |
MF | GO:0005488; binding | GO:0043546; molybdopterin cofactor binding | 1.460E-04 | 9.779E-03 | AOX1, XDH |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 1.499E-04 | 9.989E-03 | AR, ESR1, ESR2, ESRRA, ESRRB |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 2.214E-09 | 4.008E-07 | ALDH2; MAOA; CYP1A2; CYP1A1; AOX1; CYP1B1 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.819E-08 | 1.021E-06 | AR; GSK3B; CDK6; FLT3; ABL1; MAPK1; PTGS2; HIF1A; TP53; EGFR; NFKB1 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 5.474E-09 | 4.954E-07 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.238E-08 | 1.021E-06 | HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.040E-07 | 2.352E-06 | MGAM; MAOA; GAA; ALOX15; PTGS2; CYP2C19; CYP3A4; CYP19A1; CYP2C9; PKM; ALDH2; HSD17B1; TBXAS1; CYP1A2; CYP1A1; AOX1; XDH |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 5.402E-08 | 1.630E-06 | PKM; FLT3; MAPK1; TP53; HIF1A; EGFR |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 6.458E-08 | 1.670E-06 | CYP2C9; MAOA; CYP1A2; AOX1; CYP3A4; CYP2C19 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.506E-08 | 1.021E-06 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.743E-07 | 5.405E-06 | ABCC1; CDK6; ABL1; CYP1B1; MAPK1; PTGS2; TP53; EGFR; NFKB1 |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 2.986E-07 | 5.405E-06 | GSK3B; AR; MAPK1; TP53; EGFR; NFKB1 |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 4.257E-07 | 7.005E-06 | HSD17B1; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.165E-06 | 1.757E-05 | CYP2C9; MAOA; ALOX15; MAPK1; CYP2C19; PTGS2 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.264E-06 | 1.760E-05 | CYP2C9; ALOX15; TBXAS1; CYP2C19; PTGS2 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.730E-06 | 2.087E-05 | CDK6; MAPK1; TP53; EGFR; NFKB1 |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 2.929E-06 | 2.651E-05 | POLB; CDK6; PKM; SYK; MAPK1; TP53; NFKB1 |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 2.671E-06 | 2.651E-05 | GSK3B; MAPK1; ESR1; NFKB1; ESR2 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.603E-06 | 2.072E-05 | CYP2C9; CYP1A2; CYP1A1; AOX1; CYP3A4 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.860E-06 | 2.651E-05 | CDK6; ABL1; MAPK1; TP53; NFKB1 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 3.615E-06 | 3.116E-05 | GSK3B; CDK6; CSNK2A1; RAB9A; TP53; NFKB1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.491E-06 | 2.651E-05 | SLCO1B1; SLCO1B3; CYP3A4; CFTR; ABCG2 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.860E-06 | 2.651E-05 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 3.000E-05 | 2.172E-04 | GSK3B; MAPK1; TP53; ESR1; HIF1A |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 3.253E-05 | 2.264E-04 | GSK3B; ABL1; MAPK1; TP53; NFKB1 |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 7.796E-05 | 4.552E-04 | GSK3B; CDK6; SYK; MAPK1; TP53; EGFR; NFKB1 |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.554E-05 | 1.926E-04 | CDK6; MAPK1; TP53; EGFR |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.900E-05 | 1.495E-04 | GSK3B; MAPK1; TP53; EGFR |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 5.322E-05 | 3.440E-04 | GSK3B; MAPK1; TP53; EGFR; NFKB1 |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 4.613E-05 | 3.093E-04 | CDK6; MAPK1; TP53; EGFR |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 7.283E-05 | 4.394E-04 | GSK3B; SYK; MAPK1; NFKB1 |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 6.531E-05 | 4.076E-04 | CDK6; MAPK1; TP53; EGFR |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.443E-04 | 7.680E-04 | GSK3B; ABL1; MAPK1; EGFR |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.379E-04 | 7.566E-04 | CDK6; PTGS2; TP53; NFKB1 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.374E-04 | 1.194E-03 | MAPK1; ESR1; EGFR; ESR2 |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 3.760E-04 | 1.698E-03 | GSK3B; SYK; CSNK2A1; TP53; NFKB1 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 3.846E-04 | 1.698E-03 | MAPK1; TP53; HIF1A; ESR1; EGFR |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.763E-04 | 1.316E-03 | MAPK1; HIF1A; EGFR; NFKB1 |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 1.867E-04 | 9.654E-04 | SYK; CSNK2A1; PTGS2; NFKB1 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 8.810E-04 | 3.534E-03 | LMNA; MAPK1; TP53; NFKB1 |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 4.940E-04 | 2.129E-03 | ABCC1; MAPK1; TP53; NFKB1 |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.077E-03 | 3.979E-03 | MAPK1; MAPT; TP53; EGFR; NFKB1 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.030E-03 | 3.887E-03 | CDK6; MAPK1; TP53; NFKB1 |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 5.590E-04 | 2.353E-03 | GSK3B; CDK6; ABL1; TP53 |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 3.188E-03 | 1.069E-02 | MAPK1; CFTR; NFKB1; TSHR |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 5.087E-03 | 1.514E-02 | ABL1; MAPK1; EGFR; NFKB1 |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 3.638E-03 | 1.176E-02 | MAPK1; HIF1A; EGFR |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 7.025E-04 | 2.890E-03 | FLT3; MAPK1; NFKB1 |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 4.622E-03 | 1.418E-02 | MAPK1; PTGS2; NFKB1 |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 3.950E-03 | 1.233E-02 | GSK3B; MAPK1; NFKB1 |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.442E-03 | 5.222E-03 | MAPK1; PTGS2; NFKB1 |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 8.983E-04 | 3.534E-03 | GSK3B; MAPK1; TP53 |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 6.161E-03 | 1.799E-02 | SYK; TBXAS1; MAPK1 |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 7.942E-03 | 2.178E-02 | POLB; GSK3B; TP53; NFKB1 |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.500E-03 | 5.324E-03 | CSNK2A1; MAPK1; EGFR |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 7.652E-03 | 2.131E-02 | SYK; MAPK1; NFKB1 |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 9.340E-03 | 2.405E-02 | GSK3B; CSNK2A1; TP53 |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 6.883E-03 | 1.947E-02 | GSK3B; ABL1; MAPK1 |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 9.340E-03 | 2.405E-02 | GSK3B; ESRRB; MAPK1 |
hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.013E-02 | 2.462E-02 | NMUR2; ADRA2C; ADRA2A; TSHR |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.650E-04 | 1.296E-03 | MAPK1; TP53; EGFR |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 9.701E-03 | 2.433E-02 | SYK; MAPK1; EGFR |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.031E-03 | 3.887E-03 | ABL1; MAPK1; NFKB1 |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.246E-02 | 2.905E-02 | MAPK1; PTGS2; EGFR |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.445E-02 | 3.191E-02 | MAPK1; ADRA2C; ADRA2A |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.636E-02 | 3.483E-02 | GSK3B; MAPK1; NFKB1 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.468E-02 | 3.201E-02 | GSK3B; MAPK1; MAPT |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.711E-02 | 3.600E-02 | SYK; MAPK1; NFKB1 |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.762E-02 | 3.604E-02 | FLT3; TP53; NFKB1 |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 3.271E-04 | 1.518E-03 | ABCC1; CFTR; ABCG2 |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.893E-02 | 3.645E-02 | CSNK2A1; TP53; NFKB1 |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 2.380E-02 | 4.441E-02 | GSK3B; MAPK1; EGFR |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 1.947E-02 | 3.710E-02 | GSK3B; MAPK1; NFKB1 |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 1.832E-02 | 3.604E-02 | SYK; MAPK1 |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.268E-02 | 2.905E-02 | PTGS2; TSHR |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.732E-02 | 3.603E-02 | MAPK1; HIF1A |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.446E-02 | 3.191E-02 | MAPK1; HIF1A |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 1.492E-02 | 3.215E-02 | MAPK1; PTGS2 |
hsa05133 | Pertussis_Homo sapiens_hsa05133 | 2.202E-02 | 4.151E-02 | MAPK1; NFKB1 |
hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 1.883E-02 | 3.645E-02 | CDK6; TP53 |
hsa00010 | Glycolysis / Gluconeogenesis_Homo sapiens_hsa00010 | 1.782E-02 | 3.604E-02 | PKM; ALDH2 |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 1.832E-02 | 3.604E-02 | EGFR; NFKB1 |
hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.311E-02 | 2.967E-02 | MAPK1; NFKB1 |
hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.225E-02 | 2.905E-02 | GSK3B; TP53 |
hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 1.268E-02 | 2.905E-02 | MGAM; GAA |
hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 9.432E-03 | 2.405E-02 | PKM; MAPK1 |
hsa00280 | Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | 9.432E-03 | 2.405E-02 | ALDH2; AOX1 |
hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 9.814E-03 | 2.433E-02 | MAOA; NFKB1 |
hsa00330 | Arginine and proline metabolism_Homo sapiens_hsa00330 | 1.020E-02 | 2.462E-02 | ALDH2; MAOA |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 8.688E-03 | 2.347E-02 | CYP3A4; XDH |
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.781E-05 | 1.465E-04 | CA12; CA4; CA7 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 3.523E-03 | 1.159E-02 | MAPK1; TP53 |
hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 3.058E-03 | 1.044E-02 | MAPK1; EGFR |
hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 6.625E-03 | 1.903E-02 | PKM; ALDH2 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 3.768E-03 | 1.196E-02 | MGAM; GAA |
hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 5.103E-03 | 1.514E-02 | MAOA; AOX1 |
hsa00340 | Histidine metabolism_Homo sapiens_hsa00340 | 2.419E-03 | 8.419E-03 | ALDH2; MAOA |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 9.097E-05 | 5.145E-04 | CYP1A2; XDH |
hsa00750 | Vitamin B6 metabolism_Homo sapiens_hsa00750 | 1.816E-02 | 3.604E-02 | AOX1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
C00-D49: Neoplasms | Cancer | C00-C96 | AR; GSK3B; HIF1A; SYK; TP53; FLT3; FLT3; ABL1; MAPK1; NFKB1; ACHE; EGFR; ESR1; ESR1; PTGS2; CSNK2A1 |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; ESRRA |
C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; MGAM |
I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1 |
NA: NA | Male hypogonadism | NA | AR |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
C00-D49: Neoplasms | Glioma | C71 | ABL1; EGFR; EGFR |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; ADRA2C |
NA: NA | GIST | NA | FLT3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; PTGS2; ABCC1; ABCC1 |
NA: NA | Gonorrheal vaginitis | NA | ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADRA2C; ESRRA |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ABL1; EGFR; ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR |
C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; EGFR; EGFR; EGFR; ESR1; ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESR1; ESRRA |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; EGFR; EGFR; EGFR |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH; ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; TBXAS1; PTGS2; MGAM |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; SYK; TP53; FLT3; ABL1; MAPK1; EGFR; PKM |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | MGAM |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; MAOA |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle disease | M60-M63 | MGAM |
C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR; ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
NA: NA | Upper abdominal bloating | NA | ACHE |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA; MGAM |
N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1 |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
C00-D49: Neoplasms | Lung cancer | C33-C34 | ABL1; EGFR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
NA: NA | Postmenopausal disorder | NA | ESR1 |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | TBXAS1 |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | SYK; TBXAS1 |
NA: NA | Menopausal disorder | NA | ESR1 |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; EGFR; EGFR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2; ABCC1; ESRRA |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | ALDH2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1; EGFR |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Dengue fever | A90 | MGAM |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | ADRA2C; MAOA |
C00-D49: Neoplasms | Melanoma | C43 | EGFR |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GSK3B; ACHE; ACHE; ACHE; ADRA2C; MAOA; PTGS2; MAPT |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | SYK |
C00-D49: Neoplasms | AML | NA | FLT3 |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; ADRA2C |
NA: NA | Joint and muscular pain | NA | PTGS2 |
C00-D49: Neoplasms | Intestinal cancer | NA | ABL1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2C; MAOA; ALDH2 |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | SYK; PTGS2 |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | TBXAS1; PTGS2 |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | EGFR; EGFR; PTGS2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; CYP3A4; MAOA |
I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | TBXAS1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; ABL1 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; EGFR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ABL1; ESR1 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; PTGS2; PTGS2; PTGS2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK; EGFR |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | ABL1; ABL1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | ABL1 |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS2; PTGS2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
C00-D49: Neoplasms | CLL | NA | FLT3 |
C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; EGFR; PTGS2 |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; ACHE; ESR1; ADRA2C; ADRA2A; PTGS2; PTGS2; PTGS2; PTGS2; PKM |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; ALDH2 |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; ABL1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | SYK; PTGS2; PTGS2; PTGS2; PTGS2; ESRRA |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Hyperglycemia | R73.9 | MGAM |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | GSK3B; MGAM |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
J00-J99: Diseases of the respiratory system | Asthma | J45 | SYK; SYK; ADRA2C; TBXAS1; PTGS2; ESRRA |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |